

FORM PTO-1390 (Modified)
(REV 11-98)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

TRANSMITTAL LETTER TO THE UNITED STATES

DEX-0079

DESIGNATED/ELECTED OFFICE (DO/EO/US)

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR

CONCERNING A FILING UNDER 35 U.S.C. 371

09/622776

INTERNATIONAL APPLICATION NO.
PCT/US99/03170INTERNATIONAL FILING DATE
12 February 1999PRIORITY DATE CLAIMED
23 February 1998

TITLE OF INVENTION

METHODS USING PLA2 AS A MARKER OF METASTASES AND FOR THE DIAGNOSIS OF SELECTED
CANCERS

APPLICANT(S) FOR DO/EO/US

BURCZAK, John D., et al.

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
 - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ has been transmitted by the International Bureau.
 - c. ☒ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☒ A copy of the International Search Report (PCT/ISA/210).
8. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
9. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
10. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
11. ☒ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).

Items 13 to 20 below concern document(s) or information included:

13. ☒ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☒ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☐ A **FIRST** preliminary amendment.
16. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
17. ☐ A substitute specification.
18. ☐ A change of power of attorney and/or address letter.
19. ☐ Certificate of Mailing by Express Mail
20. ☒ Other items or information:

Return Post Card

"Express Mail" Label No. **EL550128207US**
Date of Deposit **AUGUST 23, 2000**

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Box PCT, Washington, D.C. 20231.

By

Deborah Ehret
Typed Name: Deborah Ehret

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR 09/622776		INTERNATIONAL APPLICATION NO. PCT/US99/03170		ATTORNEY'S DOCKET NUMBER DEX-0079	
--	--	--	--	---	--

21. The following fees are submitted:.				CALCULATIONS PTO USE ONLY	
BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) : <input type="checkbox"/> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$970.00 <input checked="" type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$840.00 <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$690.00 <input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$670.00 <input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) \$96.00					
ENTER APPROPRIATE BASIC FEE AMOUNT =					
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).				\$0.00	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	15 - 20 =	0	x \$18.00	\$0.00	
Independent claims	4 - 3 =	1	x \$78.00	\$78.00	
Multiple Dependent Claims (check if applicable). <input type="checkbox"/>				\$0.00	
TOTAL OF ABOVE CALCULATIONS =				\$918.00	
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28) (check if applicable). <input type="checkbox"/>				\$0.00	
SUBTOTAL =				\$918.00	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (f)).				\$0.00	
TOTAL NATIONAL FEE =				\$918.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable). <input checked="" type="checkbox"/>				\$40.00	
TOTAL FEES ENCLOSED =				\$958.00	
				Amount to be:	
				refunded	\$
				charged	\$

☒ A check in the amount of **\$958.00** to cover the above fees is enclosed.

☐ Please charge my Deposit Account No. _____ in the amount of _____ to cover the above fees.
A duplicate copy of this sheet is enclosed.

☒ The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. **12-1086** A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Jane Massey Licata, Reg. No. 32,257
Law Offices of Jane Massey Licata
66 E. Main Street
Marlton, New Jersey 08053

Telephone: (856) 810-1515
Facsimile : (856) 810-1454

Jane Massey Licata
SIGNATURE

LICATA, Jane Massey
NAME

32,257
REGISTRATION NUMBER

23 August 2000
DATE

METHODS USING PLA2 AS A MARKER OF METASTASES AND FOR THE DIAGNOSIS OF SELECTED CANCERS

INTRODUCTION

5 This application is a continuation of application
Serial No. 09/175,504, filed October 20, 1998 which is a
continuation-in-part of application Serial No. 09/111,938,
filed July 8, 1998, pending, which is a continuation-in-part
of provisional application Serial No. 60/075,504, filed
10 February 23, 1998.

FIELD OF THE INVENTION

This invention relates to use of PLA₂ as a metastatic marker for monitoring cancers which have not metastasized for the onset of metastasis and for diagnosing metastatic cancers. PLA₂ is demonstrated herein to be a metastatic marker for a number of different metastatic cancers including prostate, breast, colorectal, ovarian and testicular cancer. This invention also relates to methods of monitoring selected cancers including breast, ovarian and testicular cancer for progression, remission, response to therapy and stabilization in patients by monitoring PLA₂ levels in these patients. Further, the invention relates to methods which aide in identification of cancers, including testicular and ovarian cancer, among individuals who have not yet been diagnosed with these cancers by detection of elevated PLA₂ levels.

- 2 -

BACKGROUND OF THE INVENTION

Extracellular Phospholipase A₂ (PLA₂) enzymes appear to mediate a variety of responses including cellular proliferation, chemotaxis and inflammation. There are two major groups of extracellular PLA₂ enzymes: pancreatic or group I; and rheumatoid arthritis synovial fluid (RASf) or group II. The group I enzymes function in digestion and in modulating proliferation and chemotaxis. Currently, RASf-PLA₂ is predominantly believed to play a role in inflammatory responses including arthritis, septic shock and lung injury. The level of RASf-PLA₂ is regulated at the mRNA level by a variety of agents including interleukin-6, interleukin-1 and tumor necrosis factor, all of which are involved in inflammatory responses. As used hereinbelow "PLA₂" refers to group II or RASf-PLA₂. PLA₂ includes native PLA₂ (whole or a breakdown product), a native complex of molecules including PLA₂, or native chemically modified PLA₂.

Membrane-associated phospholipase A₂, M-PLA₂, has been disclosed as one of five factors suspected to play a role in the tumor cell processes and metastasis in human breast cancer (Yamashita et al., *Surgery*, 1995, 117, 601-608). Further, higher M-PLA₂ levels have been reported in breast cancer patients with distant metastasis and in patients with scirrhous carcinoma as compared to other histological types (Yamashita, *Cancer*, 1994, 69, 1166-1170). PLA₂ has also been reported to be expressed exclusively in gastric cancer cells with a low grade of differentiation and appears to be intensified in the invading zone of the tumor (Murata et al., *Br. J. Cancer*, 1993, 68(1), 103-111). Elevated M-PLA₂ was also detected in three gastric cancer cell lines (MKN28, KATO III and AZ521), in a pancreatic cancer cell line (SUIT-2), in a colonic cancer cell line (SW1116) and a hepatoblastoma cancer cell line (HuH-6). (Yamashita et al., *Clinica Chimica Acta*, 1994, 228, 91-99). In addition, patients with T2-T4 tumors or stage II-IV cancers of the lung, breast and

- 3 -

digestive organs had significantly higher levels of M-PLA₂ in comparison to stage I and T1 cancers.

PLA₂ levels have also been reported to be increased in peritoneal and pleural effusions in patients with various
5 types of cancers including gastric, breast, pancreatic, bile duct, lung, liver, esophageal and uterine cancer and cirrhotic ascites (Abe et al., *Int. J. Cancer (Pred. Oncol.)*, 1997, 74 245-250).

In addition, U.S. Patent 5,747,264 discloses a
10 diagnostic assay for detection of PLA₂ protein or PLA₂ mRNA in cells, tissues or body fluids which can be used to detect the presence of cancers, and in particular, prostate cancer. This method of quantifying PLA₂ protein levels is particularly useful for discriminating benign prostatic hyperplasia and
15 prostate cancer.

It has now been found that levels of PLA₂ in a patient can be used to diagnose and monitor various cancers for the onset of metastasis. It has also been found that determining the amount of PLA₂ in a bodily fluid of a patient
20 is useful in diagnosing various cancers and in monitoring progression, remission, response to therapy and stabilization of certain cancers in patients.

SUMMARY OF THE INVENTION

Toward these ends, and others, it is an object of the
25 present invention to provide a method of monitoring various cancers which have not metastasized for the onset of metastasis which comprises identifying a patient having a cancer that is not known to have metastasized and measuring an amount of PLA₂ in a biological fluid obtained from the
30 patient, wherein elevated levels of PLA₂ in the sample are indicative of metastasis. As demonstrated herein, PLA₂ is a metastatic marker for cancers, including prostate, breast, colorectal, ovarian and testicular cancer.

- 4 -

It is another object of the present invention to provide a method of diagnosing a metastatic cancer in a patient which comprises obtaining a sample of biological fluid from a patient; and detecting the level of PLA_2 in a sample of biological fluid, wherein elevated levels of PLA_2 in the sample are indicative of metastatic cancers.

It is another object of the present invention to provide a method for monitoring cancers, including breast, ovarian and testicular cancer, for progression, remission, response to therapy and stabilization in patients suffering from such cancers which comprises measuring levels of PLA_2 in biological fluid samples obtained from the patient at selected times, wherein an increase in the measured levels of PLA_2 over time is indicative of progressive cancer, a decrease in the measured levels of PLA_2 over time is indicative of remission or response to therapy of the cancer, and no change in the measured levels of PLA_2 over time is indicative of stabilization of the cancer.

It is another object of the present invention to provide a method to aide in identification of ovarian or testicular cancer, among individuals who have not yet been diagnosed with such cancers which comprises detecting elevated PLA_2 levels in a biological fluid obtained from a patient suspected of suffering from cancer.

Other objects, features, advantages and aspects of the present invention will become apparent to those of skill in the art from the following description. It should be understood, however, that the following description and the specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only. Various changes and modifications within the spirit and scope of the disclosed invention will become readily apparent to those skilled in the art from reading the following description and from reading the other parts of the present disclosure.

- 5 -

DESCRIPTION OF THE INVENTION

Procedures used for detecting, diagnosing, monitoring, staging, and prognosticating cancer are of critical importance to the outcome of patients suffering from cancer. Cancer patients are closely monitored following initial therapy and during adjuvant therapy to determine response to therapy and to detect persistent or recurrent disease or metastasis. Another important step in managing cancer is to determine the stage of the patient's disease. Stage determination has potential prognostic value and provides criteria for designing optimal therapy. Generally, pathological staging of cancer is preferable over clinical staging because the former gives a more accurate prognosis. However, clinical staging would be preferred were it at least as accurate as pathological staging because it does not depend on an invasive procedure to obtain tissue for pathological evaluation. Staging of cancer would be improved by detecting new markers in cells, tissues or bodily fluids which could differentiate between different stages of invasion. Accordingly, there is a need for cancer markers which are more sensitive and specific in detecting cancer recurrence and for increasingly sensitive and accurate methods for the staging of a cancer in humans to determine whether or not such cancer has metastasized and for monitoring the progress of a cancer in a human which has not metastasized for the onset of metastasis.

For example, cancer of the prostate is the most prevalent malignancy in adult males, excluding skin cancer, and is an increasingly prevalent health problem in the United States. In 1996 in the United States alone, it was estimated that 41,400 deaths would result from this disease, indicating that prostate cancer is second only to lung cancer as the most common cause of death in the same population. If diagnosed and treated early, when the cancer is still confined to the prostate, however, the chances of cure are significantly

- 6 -

higher. Further, treatment decisions for an individual are linked to the stage of prostate cancer present in that individual. A common classification of the spread of prostate cancer has been established by the American Urological Association (AUA). The AUA divides prostate tumors into four stages, A to D. Stage A, microscopic cancer within prostate, is further subdivided into stages A1 and A2. Sub-stage A1 is a well-differentiated cancer confined to one site within the prostate. Treatment generally includes observation, radical prostatectomy, or radiation. Sub-stage A2 is a moderately to poorly differentiated cancer at multiple sites within the prostate. Treatment generally includes radical prostatectomy or radiation. Stage B, which is characterized by a palpable lump within the prostate, is also subdivided into stages B1 and B2. In sub-stage B1 the cancer forms a small nodule in one lobe of the prostate. In sub-stage B2 the cancer forms large or multiple nodules, or occurs in both lobes of the prostate. Treatment for both sub-stages B1 and B2 involves either radical prostatectomy or radiation. Stage C is a large cancer mass involving most or all of the prostate and is also further subdivided into two stages. Sub-stage C1 is characterized by the cancer forming a continuous mass that may extend beyond the prostate. Sub-stage C2 is characterized by the cancer forming a continuous mass that invades the surrounding tissue. Treatment for both sub-stages C1 and C2 is radiation with or without drugs to address the cancer. The fourth stage, Stage D is metastatic cancer and is also subdivided into two stages. Sub-stage D1 is characterized by the cancer appearing in the lymph nodes of the pelvis. Sub-stage D2 is characterized by the cancer appearing in tissues beyond the lymph nodes. Treatment for both sub-stages D1 and D2 is systemic drugs to address the cancer as well as pain.

However, current prostate cancer staging methods are limited. Existing methods for diagnosing prostate cancer such as prostatic specific antigen (PSA), digital examination, and

- 7 -

transurethral ultrasound tests have difficulty discriminating between prostate cancer stages A, B, C, and D. In fact, the existing PSA diagnostic tests detect 20-28% of patients with benign prostatic hyperplasia (BPH) and 62-81% of prostate cancer patients with PSA blood levels above approximately 99% of the normal population. In addition, as many as 50% of prostate cancers initially staged as A2, B, or C have metastasized and are actually stage D. However, accurate identification of metastasis is important because patients with metastatic cancers have a poorer prognosis and require significantly different therapy than those with localized cancers.

An incorrect initial diagnosis also occurs in up to 25% of patients with testicular tumors. However, the lifetime probability of developing testicular cancer is 0.2% for an American white male. The cause of testicular cancer is unknown, however, it is associated with both congenital and acquired factors. From a treatment standpoint, testicular cancer is divided into two major categories, nonseminomas and seminomas. In the commonly used staging system for nonseminomas, a stage A lesion is confined to the testis; in stage B there is regional lymph node involvement in the retroperitoneum; and in stage C, there is distant metastasis. For seminomas, a stage I lesion is confined to the testis; in stage II, the lesion has spread to the retroperitoneal lymph nodes; and in stage III, the lesion has supradiaphragmatic nodal or visceral involvement.

The most common symptom of testicular cancer is painless enlargement of the testis. Acute testicular pain resulting from intertesticular hemorrhage occurs in about 10% of cases. Patients are often asymptomatic upon presentation but about 10% may exhibit back pain, cough or lower extremity edema. A testicular mass or diffuse enlargement of the testis can be detected by physical examination in most cases. Several biochemical markers are used for the diagnosis and

5 The most widely used biomarker for epithelial ovarian
cancer, CA125, has also been reported to lack sensitivity and
specificity (Xu et al. *JAMA*, 1998, 280 (8), 719-723). In
1995, an estimated 26,600 new cases of ovarian cancer were
diagnosed in the United States. Approximately one in 70 women
10 will develop ovarian cancer during her lifetime. An estimated
14,500 deaths in 1995 resulted from ovarian cancer. It causes
more deaths than any other cancer of the female reproductive
system.

As with most cancers, the risk of ovarian cancer increases with age. The rate is highest among women over 60 years of age. Women who have never had children are twice as likely to develop ovarian cancer as women who have. Women who already have been diagnosed with breast, intestinal or rectal cancers appear to be at increased risk of developing ovarian cancer. Early age of first pregnancy, early menopause and the use of oral contraceptives appear to reduce the risk of ovarian cancer.

Surgical treatment usually involves the removal of one or both ovaries, the uterus and the fallopian tubes. If the cancer is detected early, especially in younger women, it is possible that only the cancerous ovary will be removed. 35 Radiation and chemotherapy options also are available to

- 9 -

prevent or slow the recurrence of the ovarian cancer or the spread of cancer to other parts of the body following surgery.

It has now been found that PLA₂ levels are significantly higher in human patients with metastatic cancer as compared to cancer which has not yet metastasized.

For example, it has now been found that PLA₂ is significantly higher in human patients with metastatic Stage D prostate cancer as compared to prostate cancer which has not yet metastasized, i.e cancer in Stage A, B, or C. PLA₂ levels have also been demonstrated to be elevated in patients suffering from other progressive metastatic cancers such as breast cancer, colorectal cancer, testicular cancer and ovarian cancer. Accordingly, the present invention relates to methods of diagnosing metastatic cancer and monitoring cancers which have not metastasized for the onset of metastasis.

In this method, a patient with cancer not known to have metastasized is identified. This is accomplished by a variety of means known to those of skill in the art. For example, in the case of prostate cancer, patients are typically diagnosed with prostate cancer following digital rectal examination, serum levels of prostate specific antigen (PSA), transrectal ultrasound, and/or needle biopsy of the prostate and surrounding tissue. For ovarian cancer, patients are typically diagnosed with ovarian cancer following pelvic examination. CA125 is the most widely biomarker for detection and management of epithelial ovarian cancer. Recently, plasma lysophosphatidic acid (LPA) levels have been suggested as a potential biomarker for ovarian cancer and other gynecological cancers (Xu et al. *JAMA*, 1998, 280 (8), 719-723). In the case of testicular cancer, patients are typically diagnosed with testicular cancer following physical examination or detection of biochemical markers including human chorionic gonadotropin (hCG), alpha-fetoprotein and LDH. A sample of bodily fluid is then obtained from this patient. Bodily fluids useful in

- 10 -

the present invention include blood, urine, saliva, or any other bodily secretion or derivative thereof. By blood it is meant to include whole blood, plasma, serum, or any derivative of blood, preferably serum. PLA₂ protein or mRNA levels in the sample of bodily fluid are then determined.

Assay techniques that can be used to measure PLA₂ protein or mRNA encoding PLA₂ in a bodily fluid sample derived from a patient having cancer are well-known to those of skill in the art. Such assay methods include, without limitation, radioimmunoassays, reverse transcriptase PCR (RT-PCR) assays, immunohistochemistry assays, *in situ* hybridization assays, competitive-binding assays, Western Blot analyses, ELISA assays and proteomic approaches: two-dimensional gel electrophoresis (2D electrophoresis) and non-gel based approaches such as mass spectrometry or protein interaction profiling. Among these, enzyme immunoassays, and in particular enzyme linked immunosorbent assays (ELISAs) are frequently preferred to detect a gene's expressed protein in biological fluids. An ELISA assay initially comprises preparing an antibody, if not readily available from a commercial source, specific to PLA₂, preferably a monoclonal antibody. In addition, a reporter antibody generally is prepared which binds specifically to PLA₂. The reporter antibody is attached to a detectable reagent such as a radioactive, fluorescent or enzymatic marker, for example horseradish peroxidase enzyme or alkaline phosphatase. To carry out the ELISA, antibody specific to PLA₂ is incubated on a solid support, e.g., a polystyrene dish, that binds the antibody. Any free protein binding sites on the dish are then covered by incubating with a non-specific protein such as bovine serum albumin (BSA). Next, the bodily fluid sample to be analyzed is incubated in the dish, during which time PLA₂ binds to the specific antibody attached to the polystyrene dish. Unbound sample is washed out with buffer. A reporter antibody specifically directed to PLA₂ and linked to a

- 11 -

detectable reagent, i.e. alkaline phosphatase, is placed in the dish resulting in binding of the reporter antibody to the bound PLA₂. Unattached reporter antibody is then washed out and bound reporter antibody is detected. For example, if the

5 detectable reagent is alkaline phosphatase, reagents for alkaline phosphatase activity, including a colorimetric substrate are added to the dish. Immobilized alkaline phosphatase, linked to PLA₂ antibodies, produces a colored reaction product. The amount of color developed in a given

10 time period is proportional to the amount of PLA₂ protein present in the sample. As will be obvious to those of skill in the art upon this disclosure, other reporter antibodies and means for detecting these antibodies can also be used. Quantitative results typically are obtained by reference to

15 a standard curve.

A competition assay can also be used wherein antibodies specific to PLA₂ are attached to a solid support and labeled PLA₂ and sample obtained from the patient having cancer are passed over the solid support. The amount of label

20 detected attached to the solid support can then be correlated to a quantity of PLA₂ in the sample.

Nucleic acid methods can also be used to detect PLA₂ mRNA in a bodily fluid obtained from a patient having cancer. Examples of nucleic acid methods include, but are not limited

25 to polymerase chain reaction (PCR), ligase chain reaction (LCR) and nucleic acid based amplification (NASABA). Reverse transcriptase PCR (RT-PCR) also provides a powerful tool useful in the detection of the presence of a specific mRNA population in a complex mixture of thousands of other mRNA

30 species.

Of the proteomic approaches, 2D electrophoresis is a technique well known to those in the art. Isolation of individual proteins from a sample such as serum is accomplished using sequential separation of proteins by

35 different characteristics usually on polyacrylamide gels.

09622776.083300

- 12 -

First, proteins are separated by size using an electric current. The current acts uniformly on all proteins, so smaller proteins move farther on the gel than larger proteins. The second dimension applies a current perpendicular to the first and separates proteins not on the basis of size but on the specific electric charge carried by each protein. Since no two proteins with different sequences are identical on the basis of both size and charge, the result of a 2D separation is a square gel in which each protein occupies a unique spot. Analysis of the spots with chemical or antibody probes, or subsequent protein microsequencing can reveal the relative abundance of a given protein and the identity of the proteins in the sample.

Additional methods obvious to those of skill in the art upon this disclosure for determining PLA₂ levels in bodily fluids can also be used.

Without limiting the instant invention, typically, for a quantitative diagnostic enzyme immunoassay, a positive result indicating that the cancer in the patient being tested or monitored has metastasized is one in which bodily fluid levels of the cancer marker, PLA₂, are elevated above an established enzyme immunoassay (EIA) cut-off of 4.5 ng/ml. However, as will be obvious to those of skill in the art upon this disclosure, alternative EIA cutoffs may be established depending upon the acceptable number of false positive or false negative results for a particular patient group. In addition, in another embodiment, elevated levels of PLA₂ can be determined by comparing measured amounts in the sample of bodily fluid obtained from the human patient having cancer with amounts of this marker in the same bodily fluid type of normal human controls or previously measured amounts in the same patient. That is, if PLA₂ in serum is being measured in the patient, this amount is compared with the amount of PLA₂ in serum of normal human controls or the amount of PLA₂ measured in serum of the same patient previously. By "normal

- 13 -

human control" it is meant a random grouping of males who have not been diagnosed with prostate cancer or any other type of cancer. An increase or elevation in PLA₂ in the patient versus the amount in normal human controls or the amount previously measured in the same patient is associated with a cancer which has metastasized.

Table 1 shows the percentage of individuals identified as positive based upon measurement of PLA₂ in serum by an ELISA with an EIA cut-off of 4.5 ng/ml in normal human controls, patients having benign prostatic hyperplasia, patients having prostatitis, patients having untreated prostate cancer in Stage A, patients having untreated prostate cancer in Stage B, patients having untreated prostate cancer in Stage C, and patient newly diagnosed and treated for progressive metastasis from prostate cancer in Stage D.

Table 1
Serum Levels of PSA and PLA₂

Groups	N	PLA ₂ Positive (%) (cutoff 4.5)	PSA Positive (%)
Random Males	1573	3.4	0.0
BPH	70	2.9	27.1
Prostatitis	20	15.0	30.0
Prostate Cancer Stage A	14	7.1	78.6
Prostate Cancer Stage B	41	7.3	87.8
Prostate Cancer Stage C	17	11.8	88.2
Prostate Cancer Stage D	58	81.0	87.9

The PSA Positive value for Random Males is based upon random PSA testing. As demonstrated in this table, the percent of

- 14 -

individuals positive for PLA₂ increases significantly in patients with Stage D prostate cancer as compared to either normal human controls or patients with prostate cancer in Stage A, B or C. Accordingly, measurement of PLA₂ provides a useful means for diagnosing metastatic cancer and/or monitoring the onset of metastasis in patients with prostate cancer which has not yet metastasized.

Table 2 shows the percentage of individuals identified as positive based upon measurement of PLA₂ in serum by an ELISA with an EIA cut-off of 4.5 ng/ml in patients having breast, colorectal, ovarian or testicular cancer classified as either localized, progressive metastatic, metastatic in remission or metastatic stable.

Table 2

Serum Levels of PLA₂

Cancer Type	Localized		Progressive Met		Met Remission		Met Stable	
	N	% Pos	N	% Pos	N	% Pos	N	% Pos
Breast	4	25.0	24	83.3	8	75.0	9	44.4
Colorectal	3	33.3	20	75.0	7	85.7	5	80.0
Ovarian	1	0.0	36	72.2	1	0.0	3	33.3
Testicular	6	50.0	14	64.3	14	28.6	7	28.6

As demonstrated in this table, the percent of individuals positive for PLA₂ also increases significantly in patients with progressive breast, colorectal, ovarian and testicular metastatic cancers as compared to patients with localized cancers. Accordingly, measurement of PLA₂ provides a useful means for monitoring the onset of metastasis in patients with various types of cancer, including prostate, breast, colorectal, ovarian and testicular cancer. Further, measurement of serum PLA₂ levels at the time of diagnosis of

- 15 -

prostate, breast, colorectal, ovarian or testicular cancer or subsequently thereafter serves as an aide not only in the diagnosis of the cancer but also in determining if the newly diagnosed cancer is metastatic.

5 Further, as shown in Table 2, the percent of individuals positive for PLA₂ decreases in patients with breast, ovarian or testicular metastatic cancer that is in remission or stabilized, from the elevated percent of individuals positive for PLA₂ with progressive metastasis.

10 Accordingly, measurement of PLA₂ provides a useful means to monitor progression, remission, response to therapy or stabilization of various cancers over time. Levels of PLA₂ can be determined in biological fluid samples obtained from the patient at selected times. Times for determining PLA₂

15 levels for monitoring the progression, remission, response to therapy or stabilization of cancer in a patient can be routinely selected by one of skill in the art in accordance with the patient's history and the type of cancer which is being monitored. An increase in the measured levels of PLA₂

20 in a patient over time is indicative of progressive cancer. A decrease in the measured levels of PLA₂ in a patient over time is indicative of remission or response to therapy of the cancer. No change in the measured levels of PLA₂ in a patient over time is indicative of stabilization of the cancer.

25 As also demonstrated in Table 2, elevated PLA₂ levels in a bodily fluid obtained from a patient are also indicative of breast, colorectal, ovarian or testicular cancer in the patient. The percent of individuals positive for PLA₂ with breast, colorectal, ovarian or testicular cancer that is

30 localized, progressive metastatic, metastatic in remission, or metastatic stable is generally greater than random healthy males or females.

Patients diagnosed early with cancer generally have a much greater five-year survival rate as compared to the

35 survival rate for patients diagnosed with distant metastasized

096276-03300

- 16 -

cancer. Thus, diagnostic methods which are more sensitive and early detection of cancers are clearly needed. Accordingly, the present invention also relates to methods for diagnosing cancers, and in particular ovarian cancer or testicular cancer, in a patient by measuring PLA₂ in bodily fluids of the patient suspected of suffering from cancer. In these methods, levels of PLA₂ at least two standard deviations above levels of PLA₂ determined in healthy males are indicative of ovarian or testicular cancer. Levels of PLA₂ in patients suspected of suffering from ovarian or testicular cancer are determined in a biological fluid obtained from the patient in accordance with well known assays as described herein.

Other objects, features, advantages and aspects of the present invention will become apparent to those of skill in the art based upon this description. It should be understood, however, that the description, while indicating preferred embodiments of the invention, is given by way of illustration only. Various changes and modifications within the spirit and scope of the disclosed invention will become readily apparent to those skilled in the art from reading the present disclosure.

The following nonlimiting examples are provided to further illustrate the present invention.

EXAMPLES

25 Example 1: Quantitative immunoassay for Type II PLA₂

Microtiter plates were prepared for assays by coating a purified monoclonal antibody (SK088-3C6.16.2; Roshak et al., *J. Biol. Chem.*, 1994, 269, 25999-26005) against type II PLA₂ at a concentration of 2.0 µg/ml in 10 mM Tris-HCl buffer at pH 8.0 overnight at 2-8°C. The microtiter wells were then washed four times with 10 mM Tris-HCl at pH 7.5 containing 150 mM NaCl and 0.05% Tween-20 (TBS-T) and blocked with 1.0% BSA (Sigma A-7888) in 50 mM Tris-HCl at pH 8.0 for one hour at 21-25°C (room temperature). The microtiter plates were then

- 17 -

washed four times again with TBS-T before immediate use in the assay.

For the immunocapture assay, 200 μ l of 0.5 μ g/ml of a second monoclonal antibody (SK097-1E8.5.2; Roshak et al., 5 *J. Biol. Chem.*, 1994, 269, 25999-26005) against type II PLA₂ conjugated to biotin (Hinatownich et al., *J. Nucl. Med.*, 1987, 28, 1294-1302) in sample diluent (SPD) buffer (50 mM Tris-HCl at pH 8.0, 300 mM NaCl, 0.1% BSA, 0.05% Tween-20, 1% mouse serum (Jackson ImmunoResearch Labs 015-000-120), and 0.02% 10 NaN₃) was added to each well. Also added to the microtiter wells at this step was 10 μ l of either type II PLA₂ standard (Levin et al. *Protein Expr. Purif.* 1992, 3, 27-35) in fetal calf serum (HyClone A-1111-L) or patient serum. The plates were then incubated for 1 hour at 21-25°C with shaking. After 15 the incubation, the mixture was removed, the microtiter plates were washed 4 times with TBS-T and 100 μ l of avidin-alkaline phosphatase (Sigma A-2527) at 1.0 μ g/ml in SPD buffer were added. After a one hour incubation at 21-25°C with shaking, the wells were washed again four times with TBS-T. Finally 20 200 μ l of p-nitrophenyl phosphate at 1.0 mg/ml in 10 mM diethanolamine at pH 9.7 were added to the wells and incubated for 30 minutes at 21-25°C with shaking. Assay absorbance at 405 nm was read for each microtiter well. Assay absorbance values for purified type II PLA₂ standards were used to 25 generate a standard curve, and absorbance values for patient sample assays were compared to the standard curve to determine type II PLA₂ concentrations.

Example 2: Quantitative Assay of Prostate Specific Antigen (PSA) in Serum

30 PSA levels in serum samples of the same patients were quantified using the TANDEM-E PSA ImmunoEnzyMetric Assay (Hybritech, Inc. Sand Diego, CA) in accordance with the manufacturer's instructions.

1. A method of monitoring a cancer in a patient which has not metastasized for the onset of metastasis comprising:

2. The method of claim 1 wherein the bodily fluid is serum.

4. The method of claim 3 wherein the established enzyme immunoassay cutoff is 4.5 ng/ml.

6. A method of diagnosing a metastatic cancer in a patient comprising:

7. The method of claim 6 wherein the bodily fluid is serum.

[illegible][illegible][illegible]

The figure consists of ten separate bar charts, each representing a different error type. The x-axis for all charts lists five categories: 'Other', 'Misheard', 'Missed', 'Wrong', and 'Correct'. The y-axis represents the percentage distribution from 0% to 100%. Each chart includes a legend indicating the color-coded bars for each category.

- Chart 1:** Shows a high percentage of 'Correct' responses (approx. 85%) and very low percentages for other error types.
- Chart 2:** Shows a significant portion of 'Missed' errors (approx. 45%) along with 'Correct' responses.
- Chart 3:** Shows a mix of 'Correct' (approx. 55%), 'Missed' (approx. 35%), and 'Wrong' (approx. 10%) responses.
- Chart 4:** Shows a high percentage of 'Correct' responses (approx. 75%) and some 'Missed' errors.
- Chart 5:** Shows a high percentage of 'Correct' responses (approx. 90%) and very low percentages for other error types.
- Chart 6:** Shows a high percentage of 'Correct' responses (approx. 85%) and very low percentages for other error types.
- Chart 7:** Shows a high percentage of 'Correct' responses (approx. 85%) and very low percentages for other error types.
- Chart 8:** Shows a high percentage of 'Correct' responses (approx. 85%) and very low percentages for other error types.
- Chart 9:** Shows a high percentage of 'Correct' responses (approx. 85%) and very low percentages for other error types.
- Chart 10:** Shows a high percentage of 'Correct' responses (approx. 85%) and very low percentages for other error types.

[illegible][illegible]

The figure consists of ten separate bar charts, each representing a different error type. The x-axis for all charts lists five categories: 'Other', 'Misheard', 'Missed', 'Wrong', and 'Correct'. The y-axis represents the percentage distribution from 0% to 100%. Each chart includes a legend indicating the color-coded bars for each category.

- Chart 1:** Shows a high percentage of 'Correct' responses (approx. 85%) and very low percentages for other error types.
- Chart 2:** Shows a significant portion of 'Missed' errors (approx. 45%) along with 'Correct' responses.
- Chart 3:** Shows a mix of 'Correct' (approx. 55%), 'Missed' (approx. 35%), and 'Wrong' (approx. 10%) responses.
- Chart 4:** Shows a high percentage of 'Correct' responses (approx. 75%) and some 'Missed' errors.
- Chart 5:** Shows a high percentage of 'Correct' responses (approx. 90%) and very low percentages for other error types.
- Chart 6:** Shows a high percentage of 'Correct' responses (approx. 85%) and very low percentages for other error types.
- Chart 7:** Shows a high percentage of 'Correct' responses (approx. 85%) and very low percentages for other error types.
- Chart 8:** Shows a high percentage of 'Correct' responses (approx. 85%) and very low percentages for other error types.
- Chart 9:** Shows a high percentage of 'Correct' responses (approx. 85%) and very low percentages for other error types.
- Chart 10:** Shows a high percentage of 'Correct' responses (approx. 85%) and very low percentages for other error types.

[illegible][illegible]

- 20 -

15. The method of claim 13 wherein PLA₂ is measured by ELISA.

Docket No.
DEX-0079

Declaration and Power of Attorney For Patent Application

English Language Declaration

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

**METHODS USING PLA2 AS A MARKER OF METASTASES AND FOR THE DIAGNOSIS OF
SELECTED CANCERS**

the specification of which

(check one)

☐ is attached hereto.

☒ was filed on 12 February 1999 as United States Application No. or PCT International
Application Number PCT/US99/03170
and was amended on _____

(if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Priority Not Claimed

_____ (Number)	_____ (Country)	_____ (Day/Month/Year Filed)	<input type="checkbox"/>
_____ (Number)	_____ (Country)	_____ (Day/Month/Year Filed)	<input type="checkbox"/>
_____ (Number)	_____ (Country)	_____ (Day/Month/Year Filed)	<input type="checkbox"/>

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. (list name and registration number)

Jane Massey Licata, Reg. No. 32,257

Kathleen A. Tyrrell, Reg. No. 38,350

Laura M. Plunkett, Reg. No. 45,015

of the firm

Law Offices of Jane Massey Licata
66 E. Main Street
Marlton, New Jersey 08053

Send Correspondence to: Jane Massey Licata
Law Offices of Jane Massey Licata
66 E. Main Street
Marlton, New Jersey 08053

Direct Telephone Calls to: (name and telephone number)
Jane Massey Licata - (856) 810-1515

Full name of sole or first inventor John Burczak	
Sole or first inventor's signature <i>John D. Burczak</i>	Date 8/4/2000
Residence Santa Clara, California 6 Fox Run Road Pennington, NJ 08534	
Citizenship US	
Post Office Address Apartment 301 - 1526 Village Club	
Santa Clara, California	

Full name of second inventor, if any Francis E. Wilkinson	
Second inventor's signature <i>Francis E. Wilkinson</i>	Date 8/11/2000
Residence San Jose, California CA 3838 Jarvis Ave San Jose CA 95118	
Citizenship US	
Post Office Address 3838 Jarvis Avenue	
San Jose, California	